Market Intelligence, Clinical Progress, and High-Purity Reagents for Ewing Sarcoma and Solid Tumor Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EWSR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EWSR1 Recombinant Protein (Full-Length & Low-Complexity Domain) High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. Mammalian expressed. |
View EWSR1 Products |
| Gene Delivery | EWSR1 / EWS-FLI1 Lentivirus Premade Particles High-titer, replication-incompetent lentivirus for stable expression in cell-based oncogenesis assays. |
View EWSR1 Products |
| Benchmark Ab | Anti-EWSR1 Recombinant Antibody High-affinity positive control for Western Blot, Immunoprecipitation, and IHC. |
View EWSR1 Products |
| Validator | EWSR1 siRNA Set Target-specific knockdown verification in Ewing sarcoma cell lines. |
View EWSR1 Products |
| Related Target A | FLI1 The primary translocation fusion partner forming the oncogenic EWS-FLI1 transcription factor. |
View FLI1 Products |
| Related Target B | KDM1A (LSD1) Epigenetic partner interacting with EWS-FLI1; a validated clinical co-target. |
View KDM1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intrinsically Disordered Region (IDR) aggregation | Monomeric EWSR1 and EWS-FLI1 proteins formulated in optimized buffers to prevent non-specific precipitation during binding assays. |
| Physiological Post-Translational Modifications (PTMs) | HEK293 mammalian expression system preserves critical native methylation and phosphorylation patterns. |
| Lack of Controls | Sequence-verified clinical biosimilar antibodies and validated target-specific siRNAs included in every development panel. |
| False Positives in Transcription Factor Binding | High-purity recombinant proteins verified by SDS-PAGE and Mass Spectrometry to guarantee structural integrity. |
Live EWSR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EWSR1 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic agents to targeted transcriptional inhibitors and protein degraders (PROTACs). Because the wild-type EWSR1 serves critical housekeeping RNA-binding functions, selective targeting of the oncogenic fusion product (EWS-FLI1) or its downstream transcriptional complexes represents the primary avenue for next-generation drug discovery. As first-generation direct inhibitors navigate clinical hurdles, the next wave of R&D is targeting epigenetic co-factors, biomolecular condensates, and target-specific protein degradation pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Transcription Inhibitors) | Salarius Pharmaceuticals, Oncternal Oncology | Ewing Sarcoma, Prostate Cancer | Protein-Protein Interaction (PPI) assays (Requires high-purity, stable EWSR1/FLI1 proteins). |
| Targeted Protein Degraders (PROTACs/Glues) | Academic institutions, Biotech startups | Refractory Solid Tumors | Ternary complex validation assays (Requires sequence-verified, natively folded EWSR1/EWS-FLI1 targets). |
| RNA Interference (siRNA/ASO) | Gradalis, Inc. | Advanced Ewing Sarcoma | In vitro knockdown validation (Requires high-specificity EWSR1 siRNA controls). |